Retatrutide Approval Timeline: Research Milestones
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Development milestones and approval
Retatrutide remains investigational and is not FDA-approved as of September 27, 2026. Lilly stated in its July 23, 2026 announcement that it plans a Biologics License Application submission in the first quarter of 2027. That is a sponsor plan, not an FDA decision or guaranteed approval date.
Completion of a study, publication of results, application submission, acceptance for review and approval are separate milestones. Positive findings do not determine the final indication, warnings, product availability or price. Forecasts should be attributed and dated, rather than presented as established clinical access.
FDA states that retatrutide cannot be used in compounding under federal law. A local clinic or online platform cannot create an approved access pathway by advertising a prescription or a future waitlist. Research participation remains subject to individual study requirements.